Menopause

  • New resource tool aims to advance women’s health research

    A new government-backed platform has been launched in the US to help close the gaps in women's health research and patient outcomes. The U.S National Library of Medicine (NLM) and the Office of Research on Women's Health (ORWH) have launched the Discover Women’s Health (DiscoverWHR) Resource which aims to close the gaps in women’s health [...]

  • Awards to shine a spotlight on AI innovation

    The Femtech World Awards 2025, delivered in partnership with headline sponsor Planned Parenthood, celebrates the brightest lights in women's health innovation. We will be celebrating some of the best examples of leadership, innovation and impact in key areas that affect women's health and wellbeing. The AI Innovation award celebrates innovative AI-driven solutions that address critical [...]

  • The best menopause products, services and tools for 2025

    Femtech World showcases some of the most innovative and impactful menopause products, tools and services that could help you in the year ahead. Recent years have seen a surge in the range and volume of products aimed at addressing challenges associated with the menopause. This comes as more and more health and wellbeing innovators turn [...]

  • OB-GYN innovators to be recognised at Femtech World Awards

    The Femtech World Awards 2025, delivered in partnership with headline sponsor Planned Parenthood, celebrates the brightest lights in women's health innovation. The event celebrates the best examples of leadership, innovation and impact in key areas that affect women's health and wellbeing. The OB/GYN Innovation of the Year award recognises a pioneering advancement that has transformed [...]

  • Study links asthma with later age menopause

    Researchers have identified asthma as a risk factor associated with later age menopause. Many studies suggest that an earlier age at menopause is more detrimental to a woman’s health, leading to an increased risk for adverse health conditions such as heart disease, diabetes, osteoporosis, and depression, among others. However, a new study is linking a later age [...]

  • The complex relationship between brain health and menopausal hormone therapy

    A study suggests that menopausal hormone therapy (MHT) might have moderate effects on brain health, but this depends on past surgical history, the duration of treatment, and a woman’s age at last use. The research investigates the associations between MHT and brain health in a large population of UK women. Ovarian hormones such as oestrogens [...]

  • 10-year study shows deep inequalities in menopause treatment access

    A study of menopausal women in England has found that those in affluent areas are twice as likely to be offered hormone replacement therapy (HRT) than those in socially deprived areas. As the Guardian reports, the findings also show that women of Chinese or black African background are 80 per cent less likely to receive [...]

  • Women “still in the dark” on perimenopause – report

    A poll of women in every US state has found that one in four respondents experience perimenopause symptoms before 35. It also suggests that the most commonly experienced perimenopause symptoms are mood changes (92 per cent), anxiety (90 per cent), bloating (90 per cent), decreased interest in sex (80 per cent), and difficulty sleeping (80 [...]

  • UK government appoints new menopause employment role

    Journalist and women’s equality campaigner, Mariella Frostrup, has been appointed as the UK government’s new menopause employment ambassador. The voluntary role will see Mariella working closely with employers across the country to improve workplace support for women experiencing the menopause, raise awareness of the symptoms and champion the economic contributions of women. A key focus [...]

  • Menopause drug moves a step closer to patient usage

    A treatment for hot flashes developed by global pharma firm Bayer has had its new drug application accepted by the US Food and Drug Administration (FDA). The investigational compound elinzanetant is designed for the treatment of moderate-to-severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause. The new drug application (NDA) acceptance means [...]